Robert T Jensen

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Pancreatic endocrine tumors: recent advances
    R T Jensen
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
    Ann Oncol 10:170-6. 1999
  2. pmc International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states
    R T Jensen
    Digestive Diseases Branch, National Institute of Diabetes Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Pharmacol Rev 60:1-42. 2008
  3. ncbi request reprint Gastrinoma (duodenal and pancreatic)
    Robert T Jensen
    Digestive Diseases Branch, NIH, Bethesda, MD 20892, USA
    Neuroendocrinology 84:173-82. 2006
  4. ncbi request reprint Well-differentiated duodenal tumor/carcinoma (excluding gastrinomas)
    Robert T Jensen
    Digestive Diseases Branch, NIDDK, NIH, Bethesda, MD, USA
    Neuroendocrinology 84:165-72. 2006
  5. pmc Definition of the role of somatostatin receptor scintigraphy in gastrointestinal neuroendocrine tumor localization
    R T Jensen
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Yale J Biol Med 70:481-500. 1997
  6. ncbi request reprint Gastrinomas: advances in diagnosis and management
    Robert T Jensen
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
    Neuroendocrinology 80:23-7. 2004
  7. ncbi request reprint Importance of amino acids of the central portion of the second intracellular loop of the gastrin-releasing Peptide receptor for phospholipase C activation, internalization, and chronic down-regulation
    Michael Schumann
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 10, Rm 9C 103, 10 Center Drive, MSC 1804, Bethesda, MD 20892, USA
    J Pharmacol Exp Ther 307:597-607. 2003
  8. ncbi request reprint Involvement of cholecystokinin/gastrin-related peptides and their receptors in clinical gastrointestinal disorders
    Robert T Jensen
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892 1804, USA
    Pharmacol Toxicol 91:333-50. 2002
  9. ncbi request reprint Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas
    Robert T Jensen
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892 1804, USA
    Basic Clin Pharmacol Toxicol 98:4-19. 2006
  10. pmc Gastrointestinal growth factors and hormones have divergent effects on Akt activation
    Marc J Berna
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892 1804, USA
    Cell Signal 21:622-38. 2009

Collaborators

Detail Information

Publications126 found, 100 shown here

  1. ncbi request reprint Pancreatic endocrine tumors: recent advances
    R T Jensen
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
    Ann Oncol 10:170-6. 1999
    ..Each of these areas will be briefly highlighted in this presentation...
  2. pmc International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states
    R T Jensen
    Digestive Diseases Branch, National Institute of Diabetes Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Pharmacol Rev 60:1-42. 2008
    ..This review summarizes advances in our understanding of the biology/pharmacology of these receptors, including their classification, structure, pharmacology, physiology, and role in pathophysiological conditions...
  3. ncbi request reprint Gastrinoma (duodenal and pancreatic)
    Robert T Jensen
    Digestive Diseases Branch, NIH, Bethesda, MD 20892, USA
    Neuroendocrinology 84:173-82. 2006
  4. ncbi request reprint Well-differentiated duodenal tumor/carcinoma (excluding gastrinomas)
    Robert T Jensen
    Digestive Diseases Branch, NIDDK, NIH, Bethesda, MD, USA
    Neuroendocrinology 84:165-72. 2006
  5. pmc Definition of the role of somatostatin receptor scintigraphy in gastrointestinal neuroendocrine tumor localization
    R T Jensen
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Yale J Biol Med 70:481-500. 1997
    ....
  6. ncbi request reprint Gastrinomas: advances in diagnosis and management
    Robert T Jensen
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
    Neuroendocrinology 80:23-7. 2004
    ..Recent data from our NIH prospective studies on patients with ZES are included to illustrate many of these points...
  7. ncbi request reprint Importance of amino acids of the central portion of the second intracellular loop of the gastrin-releasing Peptide receptor for phospholipase C activation, internalization, and chronic down-regulation
    Michael Schumann
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 10, Rm 9C 103, 10 Center Drive, MSC 1804, Bethesda, MD 20892, USA
    J Pharmacol Exp Ther 307:597-607. 2003
    ....
  8. ncbi request reprint Involvement of cholecystokinin/gastrin-related peptides and their receptors in clinical gastrointestinal disorders
    Robert T Jensen
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892 1804, USA
    Pharmacol Toxicol 91:333-50. 2002
    ..The evidence for their possible involvement in mediating growth of gastric and pancreatic tumours and possible involvement of gastrin-related peptides in colon cancers, is reviewed briefly...
  9. ncbi request reprint Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas
    Robert T Jensen
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892 1804, USA
    Basic Clin Pharmacol Toxicol 98:4-19. 2006
    ..In this paper, results from studies of Zollinger-Ellison syndrome patients and other recent studies dealing with the safety concerns above, are briefly reviewed...
  10. pmc Gastrointestinal growth factors and hormones have divergent effects on Akt activation
    Marc J Berna
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892 1804, USA
    Cell Signal 21:622-38. 2009
    ..This regulation is complex with phospholipase C agents such as CCK, because both stimulatory and inhibitory effects can be seen, which are mediated by different mechanisms...
  11. pmc CCK causes PKD1 activation in pancreatic acini by signaling through PKC-delta and PKC-independent pathways
    Marc J Berna
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health NIH, Bethesda, MD 20892 1804, USA
    Biochim Biophys Acta 1773:483-501. 2007
    ..CCK stimulated translocation of total and phosphorylated PKD1 to the membrane. These results demonstrate that CCK(A) receptor activation leads to PKD activation by signaling through PKC-dependent and PKC-independent pathways...
  12. ncbi request reprint Camptothecin-somatostatin conjugates inhibit the growth of small cell lung cancer cells
    Terry W Moody
    DHHS, NIH, NCI Office of the Director, CCR, 31 Center Drive, Bethesda, MD 20892, USA
    Peptides 26:1560-6. 2005
    ..These results suggest that CPT conjugated peptides such as CPT-L1-SSA may prove useful for exploring the efficacy of receptor-directed cytotoxicity to inhibit the proliferation of SCLC cells...
  13. ncbi request reprint Zollinger-Ellison syndrome revisited: diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion
    Fathia Gibril
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 10, Room 9C 103, 10 Center Drive MSC 1804, Bethesda, MD 20892 1804, USA
    Curr Gastroenterol Rep 6:454-63. 2004
    ..Finally, almost every patient with ZES has marked gastric acid hypersecretion, and its current treatment as well as the long-term possible side effects are reviewed briefly...
  14. ncbi request reprint Elucidation of the vasoactive intestinal peptide pharmacophore for VPAC(2) receptors in human and rat and comparison to the pharmacophore for VPAC(1) receptors
    Hisato Igarashi
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases NIH, Building 10, 10 Center Drive, Bethesda, MD 20892, USA
    J Pharmacol Exp Ther 303:445-60. 2002
    ..These results of our study should be useful for designing VPAC subtype-selective analogs, simplified analogs, and possibly metabolically stable analogs...
  15. ncbi request reprint Gastrointestinal hormones cause rapid c-Met receptor down-regulation by a novel mechanism involving clathrin-mediated endocytosis and a lysosome-dependent mechanism
    K Martin Hoffmann
    Digestive Diseases Branch, NIDDK, National Institutes of Health, Bethesda, Maryland 20892 1804, USA
    J Biol Chem 281:37705-19. 2006
    ..These results show CCK and other GI hormones can cause rapid c-Met down-regulation, which occurs by a novel mechanism. These results could be important for c-Met regulation in normal as well as in neoplastic tissue in the GI tract...
  16. pmc Pharmacology of putative selective hBRS-3 receptor agonists for human bombesin receptors (BnR): affinities, potencies and selectivity in multiple native and BnR transfected cells
    Veronica Sancho
    Digestive Diseases Branch, NIDDK, National Institutes of Health, Bethesda, MD 20892 1804, USA
    Peptides 31:1569-78. 2010
    ..This study underscores the importance of full pharmacological characterization of newly reported selective agonists...
  17. pmc Secretin-receptor and secretin-receptor-variant expression in gastrinomas: correlation with clinical and tumoral features and secretin and calcium provocative test results
    Scott H Long
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Clin Endocrinol Metab 92:4394-402. 2007
    ..It is unknown whether the tumor density of secretin receptors or the presence of a secretin-receptor-variant, which can act as a dominant negative, is important. The aim of this study was to investigate these possibilities...
  18. ncbi request reprint Meningiomas may be a component tumor of multiple endocrine neoplasia type 1
    Behnam Asgharian
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases NIH, Building 10, 10 Center Drive MSC 1804, Bethesda, MD 20892 1804, USA
    Clin Cancer Res 10:869-80. 2004
    ..The aim of this study was to address these two latter questions...
  19. pmc Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells
    Terry W Moody
    Department of Health and Human Services, National Cancer Institute, Center for Cancer Research, Office of the Director, Bethesda, Maryland 20892, USA
    Eur J Pharmacol 637:38-45. 2010
    ..The results indicate that the NMB receptor regulates EGF receptor transactivation by a mechanism dependent on Src as well as metalloprotease activation and generation of reactive oxygen species...
  20. doi request reprint Utility of intraoperative parathyroid hormone monitoring in patients with multiple endocrine neoplasia type 1-associated primary hyperparathyroidism undergoing initial parathyroidectomy
    Naris Nilubol
    Endocrine Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, MSC1201 Room 3 3940, Bethesda, MD 20892 1201, USA
    World J Surg 37:1966-72. 2013
    ..Intraoperative parathyroid hormone monitoring (IOPTH) is a widely used adjunct for primary hyperparathyroidism (pHPT). However, the benefit of IOPTH in familial pHPT, such as in multiple endocrine neoplasia type I (MEN1), remains unclear...
  21. ncbi request reprint Cholecystokinin-stimulated protein kinase C-delta kinase activation, tyrosine phosphorylation, and translocation are mediated by Src tyrosine kinases in pancreatic acinar cells
    Jose A Tapia
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892 1804, USA
    J Biol Chem 278:35220-30. 2003
    ..Activation of Src kinases is essential for the tyrosine phosphorylation and kinase activation to occur and plays a partial role in translocation...
  22. pmc Gastrointestinal hormones stimulate growth of Foregut Neuroendocrine Tumors by transactivating the EGF receptor
    Alessia Di Florio
    Digestive Diseases Branch, NIDDK, National Institutes of Health, Bethesda, MD 20892 1804, USA
    Biochim Biophys Acta 1833:573-82. 2013
    ..These results raise the possibility that disruption of this signaling cascade by either EGFR inhibition alone or combined with receptor antagonists may be a novel therapeutic approach for treatment of foregut NETs/PETs...
  23. pmc The molecular basis for high affinity of a universal ligand for human bombesin receptor (BnR) family members
    Hirotsugu Uehara
    Digestive Diseases Branch, NIDDK, National Institutes of Health, Bethesda, MD 20892 1804, USA
    Biochem Pharmacol 84:936-48. 2012
    ....
  24. ncbi request reprint In vitro and in vivo antitumor effects of cytotoxic camptothecin-bombesin conjugates are mediated by specific interaction with cellular bombesin receptors
    Terry W Moody
    Department of Health and Human Services, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Pharmacol Exp Ther 318:1265-72. 2006
    ..Because many tumors overexpress Bn receptors, these results also demonstrate that CPT-L2-BA3 will be a useful agent for delivering receptor-mediated cytotoxicity to many different human tumors...
  25. pmc SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner
    Terry W Moody
    Department of Health and Human Services, National Cancer Institute, Center for Cancer Research, Office of the Director, Bethesda, MD 20892, USA Electronic address
    Life Sci 100:25-34. 2014
    ..The mechanism by which SR48692 inhibits non-small cell lung cancer (NSCLC) proliferation was investigated...
  26. pmc Association of type-O blood with neuroendocrine tumors in multiple endocrine neoplasia type 1
    Allison B Weisbrod
    Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Clin Endocrinol Metab 98:E109-14. 2013
    ..We recently reported an association between O blood type and the manifestation of pancreatic neuroendocrine tumors in a cohort of patients with Von Hippel-Lindau syndrome...
  27. pmc Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs
    Hirotsugu Uehara
    Digestive Diseases Branch, NIDDK, National Institutes of Health, Bethesda, MD 20892 1804, USA
    Peptides 32:1685-99. 2011
    ..The current study provides affinities/potencies on a large number of potential agonists that might be useful for human studies...
  28. pmc Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors
    Nieves Gonzalez
    Digestive Diseases Branch, NIDDK, and Department of Health and Human Services, National Institutes of Health, Bethesda, MD 20892 1804, United States
    Peptides 30:1473-86. 2009
    ..However, a number were identified which were potent/selective for human Bn-receptors and should be useful for investigating their roles in human physiological/pathophysiological conditions...
  29. ncbi request reprint Identification of key amino acids in the gastrin-releasing peptide receptor (GRPR) responsible for high affinity binding of gastrin-releasing peptide (GRP)
    Tomoo Nakagawa
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases NIDDK, National Institutes of Health, Bethesda, MD 20892 1804, USA
    Biochem Pharmacol 69:579-93. 2005
    ....
  30. pmc Molecular basis for agonist selectivity and activation of the orphan bombesin receptor subtype 3 receptor
    Nieves Gonzalez
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Heath, Building 10, Room 9C 103, 10 CENTER DR MSC 1804, Bethesda, MD 20892 1804, USA
    J Pharmacol Exp Ther 324:463-74. 2008
    ....
  31. pmc Molecular basis for the selectivity of the mammalian bombesin peptide, neuromedin B, for its receptor
    Nieves Gonzalez
    Digestive Diseases Branch, NIDDK, NIH, Bethesda, MD 20892 1804, USA
    J Pharmacol Exp Ther 331:265-76. 2009
    ..The effect at position 199 is primarily due to differences in hydrophobicity of the substitution, whereas steric factors and charge of the substitution at position 203 were important determinants of NMB selectivity...
  32. ncbi request reprint Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature
    Marc J Berna
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892 1804, USA
    Medicine (Baltimore) 85:295-330. 2006
    ..In conclusion, this detailed analysis of FSG in a large number of patients with ZES allowed us to identify important clinical guidelines that should contribute to improved diagnosis and management of patients with ZES...
  33. pmc A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors
    Marc J Berna
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892 1804, USA
    J Clin Endocrinol Metab 93:1582-91. 2008
    ..ECL-cell changes have been extensively studied in sporadic ZES patients and can be precursor lesions of gastric carcinoids, but little is known about factors influencing their severity or development of carcinoids in MEN1/ZES patients...
  34. ncbi request reprint Nonpeptide gastrin releasing peptide receptor antagonists inhibit the proliferation of lung cancer cells
    Terry W Moody
    Department of Health and Human Services, National Institutes of Health, Office of the Director, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Eur J Pharmacol 474:21-9. 2003
    ..These results indicate that PD176252 is a gastrin releasing peptide receptor antagonist, which inhibits the proliferation of lung cancer cells...
  35. ncbi request reprint Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases
    Masayuki Furukawa
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Hematopathology Section, Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, Maryland 20892 1804, USA
    Clin Cancer Res 11:3233-42. 2005
    ..Whether this is true of neuroendocrine tumors such as gastrinomas is unclear. The aim of this study was to address this question in gastrinomas...
  36. pmc PYK-2 is tyrosine phosphorylated after activation of pituitary adenylate cyclase activating polypeptide receptors in lung cancer cells
    Terry W Moody
    NCI Office of the Director, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    J Mol Neurosci 48:660-6. 2012
    ..The increase in PYK-2 tyrosine phosphorylation caused by PACAP was inhibited by PACAP(6-38), U73122, or BAPTA, but not H89. The results suggest that PAC1 regulates PYK-2 tyrosine phosphorylation in a calcium-dependent manner...
  37. ncbi request reprint X-chromosome loss of heterozygosity frequently occurs in gastrinomas and is correlated with aggressive tumor growth
    Yuan Jia Chen
    Digestive Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer 100:1379-87. 2004
    ..Therefore, the purpose of the current study was to determine whether X-chromosome LOH occurred in gastrinomas and, if so, whether it was correlated with tumor growth, tumor behavior, and/or prognosis...
  38. ncbi request reprint Activation of Gab1 in pancreatic acinar cells: effects of gastrointestinal growth factors/hormones on stimulation, phosphospecific phosphorylation, translocation and interaction with downstream signaling molecules
    K Martin Hoffmann
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg 10, Room 9C 103, 10 CENTER DR MSC 1804, Bethesda, MD, 20892 1804, United States
    Cell Signal 18:942-54. 2006
    ..e., growth/regeneration)...
  39. pmc Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells
    Terry W Moody
    National Cancer Institute, Office of the Director, Center for Cancer Research, Bethesda, MD 20892 1500, USA
    Lung Cancer 68:154-60. 2010
    ..Because S-valproate and S-diclofenac inhibit the growth of NSCLC cells and reduce PGE(2) levels, they may prove beneficial in the chemoprevention and/or therapy of NSCLC...
  40. pmc Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states
    Nieves Gonzalez
    Digestive Diseases Branch, National Institutes of Health, Bethesda, Maryland 20892, USA
    Curr Opin Endocrinol Diabetes Obes 15:58-64. 2008
    ..The purpose of this review is to highlight advances in the understanding of these peptides in physiology/disease states...
  41. pmc Vasoactive intestinal peptide-camptothecin conjugates inhibit the proliferation of breast cancer cells
    Terry W Moody
    Department of Health and Human Services, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, United States
    Peptides 28:1883-90. 2007
    ..125)I-(A-NL-K)VIP-L2-CPT was internalized by MCF7 cells at 37 degrees C but not 4 degrees C. These results indicate that (A-NL-K)VIP-L2-CPT is a VPAC(1)-R agonist which is cytotoxic for breast cancer cells...
  42. pmc Mechanism of acid hypersecretion post curative gastrinoma resection
    Jeremiah V Ojeaburu
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg 10, Rm 9C 103, 10 CENTER DR MSC 1804, Bethesda, MD 20892 1804, USA
    Dig Dis Sci 56:139-54. 2011
    ..Some patients with Zollinger-Ellison syndrome post curative gastrinoma resection continue to show gastric acid hypersecretion; however, the mechanism is unknown...
  43. ncbi request reprint Bombesin/gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation
    Terry W Moody
    Department of Health and Human Services, Office of the Director, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA
    J Mol Neurosci 28:231-8. 2006
    ..These results indicate that GRP receptor antagonists may potentiate the action of histone deacetylase inhibitors on lung cancer cellular proliferation by increasing expression of tumor suppressor genes...
  44. ncbi request reprint Molecular basis of the selectivity of gastrin-releasing peptide receptor for gastrin-releasing peptide
    Kenji Tokita
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892 1804, USA
    Mol Pharmacol 61:1435-43. 2002
    ..Our results suggest that an interaction between the aromatic ring of Phe(185) of the GRPR with GRP is the most important for GRP selectivity...
  45. ncbi request reprint Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas
    Alaa Abou-Saif
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892 1804, USA
    Cancer 98:249-61. 2003
    ..In this prospective study of patients with gastrinomas, serial changes in serum CgA levels were compared with changes in levels of the specific tumor marker gastrin to determine whether they reflected changes in tumor burden...
  46. ncbi request reprint Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new
    Marc J Berna
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892 1804, USA
    Medicine (Baltimore) 85:331-64. 2006
    ..For secretin testing, the criterion with the highest sensitivity and specificity is an increase of > or =120 pg/mL, which should replace other criteria commonly used today...
  47. ncbi request reprint The Src family kinase, Lyn, is activated in pancreatic acinar cells by gastrointestinal hormones/neurotransmitters and growth factors which stimulate its association with numerous other signaling molecules
    Andrea Pace
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892 1804, USA
    Biochim Biophys Acta 1763:356-65. 2006
    ....
  48. ncbi request reprint Development of bombesin analogs with conformationally restricted amino acid substitutions with enhanced selectivity for the orphan receptor human bombesin receptor subtype 3
    Samuel A Mantey
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg 10, Room 9C 103, 10 Center Dr, MSC 1804, Bethesda, MD 20892 1804l, USA
    J Pharmacol Exp Ther 310:1161-70. 2004
    ..This enhanced selectivity should allow this analog to be useful for investigating the possible role of hBRS-3 in physiological or pathological processes...
  49. ncbi request reprint Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature
    Fathia Gibril
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892 1804, USA
    Medicine (Baltimore) 83:43-83. 2004
    ..In this study we have identified a number of important clinical and laboratory features of MEN1/ZES that were not previously appreciated, which should contribute to earlier diagnosis and improve both short- and long-term management...
  50. ncbi request reprint Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1
    Fathia Gibril
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health NIH, Bethesda, Maryland 20892, USA
    J Clin Endocrinol Metab 88:1066-81. 2003
    ..This study provides information on early thymic carcinoids and allows modifications of existing guidelines to be recommended for their diagnosis, surveillance, and treatment...
  51. ncbi request reprint Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability
    Paolo L Peghini
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 8:2273-85. 2002
    ..Whether this is true of neuroendocrine tumors such as gastrinomas is unclear...
  52. ncbi request reprint Pancreatic Stellate Cells and CX3CR1: Occurrence in Normal Pancreas and Acute and Chronic Pancreatitis and Effect of Their Activation by a CX3CR1 Agonist
    Masahiko Uchida
    From the Department of Medicine and Bioregulatory Science, Kyushu University, Fukuoka, Japan Department of Cell Biology Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD and Department of Leprosy Research Center, National Institute of Infectious Diseases, Tokyo, Japan
    Pancreas 43:708-19. 2014
    ..Therefore, we investigated CX3CL1 receptor (CX3CR1) occurrence in normal pancreas and pancreatitis (acute/chronic) tissues and the effects of CX3CL1 on activated PSCs...
  53. pmc Comparative pharmacology of bombesin receptor subtype-3, nonpeptide agonist MK-5046, a universal peptide agonist, and peptide antagonist Bantag-1 for human bombesin receptors
    Paola Moreno
    Digestive Diseases Branch P M, S M, B N B, R T J and Diabetes, Endocrinology, and Obesity Branch M L R, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland Department of Metabolism, Nutrition and Hormones N G, IIS Fundación Jiménez Díaz, Madrid, Spain Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas CIBERDEM, Madrid, Spain and Peptide Research Laboratories, Department of Medicine, Tulane Health Sciences Center, New Orleans, Louisiana D H C
    J Pharmacol Exp Ther 347:100-16. 2013
    ..These results show that their hBRS-3 receptor activation is not always concordant and could lead to markedly different cellular responses. ..
  54. ncbi request reprint Multiple endocrine neoplasia type 1 variant with frequent prolactinoma and rare gastrinoma
    Wei Hao
    Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Clin Endocrinol Metab 89:3776-84. 2004
    ..MEN1 carriers in such families should have periodic monitoring adjusted for the expected penetrance of tumors...
  55. pmc Bombesin receptor subtype-3 agonists stimulate the growth of lung cancer cells and increase EGF receptor tyrosine phosphorylation
    Terry W Moody
    Department of Health and Human Services, National Cancer Institute, Center for Cancer Research, Office of Director, Bethesda, MD 20892, USA
    Peptides 32:1677-84. 2011
    ..These results demonstrate that BRS-3 agonists may stimulate lung cancer growth as a result of EGFR transactivation and that the transactivation is regulated by BRS-3 in a Src-, reactive oxygen and matrix metalloprotease-dependent manner...
  56. ncbi request reprint Development of high affinity camptothecin-bombesin conjugates that have targeted cytotoxicity for bombesin receptor-containing tumor cells
    Terry W Moody
    Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Biol Chem 279:23580-9. 2004
    ..It therefore should be a useful prototype to explore the effectiveness of tumor-specific cytotoxicity delivery using a receptor-mediated mechanism...
  57. ncbi request reprint Duodenal neuroendocrine tumors: Classification, functional syndromes, diagnosis and medical treatment
    K Martin Hoffmann
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg 10, Rm 9C 103, 10 Center Dr, MSC 1804, Bethesda, MD 20892 1804, USA
    Best Pract Res Clin Gastroenterol 19:675-97. 2005
    ..In this chapter, their epidemiology, clinical aspects, localization, diagnosis and medical treatment are reviewed including the latest advances in each area...
  58. ncbi request reprint Development of simplified vasoactive intestinal peptide analogs with receptor selectivity and stability for human vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors
    Hisato Igarashi
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda MD 20892 1804, USA
    J Pharmacol Exp Ther 315:370-81. 2005
    ....
  59. pmc Pituitary adenylate cyclase-activating polypeptide causes tyrosine phosphorylation of the epidermal growth factor receptor in lung cancer cells
    Terry W Moody
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 31, Room 4A48, 31 Center Drive, Bethesda, MD 20892, USA
    J Pharmacol Exp Ther 341:873-81. 2012
    ..The results indicate that PACAP causes transactivation of the EGFR in NSCLC cells in an oxygen-dependent manner that involves phospholipase C but not protein kinase A...
  60. doi request reprint Preoperative localizing studies for initial parathyroidectomy in MEN1 syndrome: is there any benefit?
    Naris Nilubol
    Endocrine Oncology Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, MSC1201 Rm 3 3940, Bethesda, MD 20892 1201, USA
    World J Surg 36:1368-74. 2012
    ..The objective of the present study was to evaluate the utility of preoperative localizing studies in patients with MEN1 undergoing initial bilateral neck exploration (BNE) and parathyroidectomy for pHPT...
  61. ncbi request reprint Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas
    Paolo L Peghini
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892 1804, USA
    Gastroenterology 123:68-85. 2002
    ..Studies of patients with sporadic Zollinger-Ellison syndrome (ZES) allow this separation...
  62. ncbi request reprint Identification of bombesin receptor subtype-specific ligands: effect of N-methyl scanning, truncation, substitution, and evaluation of putative reported selective ligands
    Samuel A Mantey
    DHHS NIH, NIDDK, DDB, Bldg 10, Rm 9C103, 31 Center Drive, Bethesda, MD 20892, USA
    J Pharmacol Exp Ther 319:980-9. 2006
    ..However, both of these analogs should be useful templates to develop more selective BRS-3 ligands...
  63. ncbi request reprint Patients with multiple endocrine neoplasia type 1 with gastrinomas have an increased risk of severe esophageal disease including stricture and the premalignant condition, Barrett's esophagus
    K Martin Hoffmann
    Digestive National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases Digestive Diseases Branch, Bethesda, Maryland 20892 1804, USA
    J Clin Endocrinol Metab 91:204-12. 2006
    ..Although esophageal reflux symptoms are common in these patients, little is known about long-term occurrence of severe peptic esophageal disease including strictures and Barrett's esophagus (BE)...
  64. ncbi request reprint PACAP-27 tyrosine phosphorylates mitogen activated protein kinase and increases VEGF mRNAs in human lung cancer cells
    Terry W Moody
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Regul Pept 109:135-40. 2002
    ..Addition of VIP to NCI-H1299 cells caused increased VEGF mRNA, which was totally inhibited by H89, a PKA inhibitor. These results suggest that PAC(1) and VPAC(1) receptors regulate VEGF expression in lung cancer cells...
  65. ncbi request reprint Phosphospecific site tyrosine phosphorylation of p125FAK and proline-rich kinase 2 is differentially regulated by cholecystokinin receptor type A activation in pancreatic acini
    Andrea Pace
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Biol Chem 278:19008-16. 2003
    ..These results show that phosphorylation of these different sites is differentially regulated and involves different intracellular mechanisms in the same cell...
  66. ncbi request reprint VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice
    Terry W Moody
    Department of Health and Human Services, National Institutes of Health, NCI Office of the Director, Center for Cancer Research, NCI, Bethesda, MD 20892, USA
    Life Sci 74:1345-57. 2004
    ..Because VPAC1 receptor antagonists increase the survival and reduce the tumor burden in C3(1)SV40Tag mice, they may function as chemopreventive agents in mammary cancer...
  67. ncbi request reprint Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness
    Stephan U Goebel
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland 20892 1804, USA
    Cancer Res 62:3702-10. 2002
    ..Therefore, HER-2/neu levels could have prognostic significance as well as identify a patient subset with gastrinomas who might benefit from trastuzumab treatment...
  68. ncbi request reprint Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome
    Fathia Gibril
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892 1804, USA
    Curr Gastroenterol Rep 7:114-21. 2005
    ..Recently, a number of important studies have examined their molecular pathogenesis and natural history and provided important guidelines for their treatment. Each of these areas is briefly reviewed in this article...
  69. ncbi request reprint Results of initial operation for hyperparathyroidism in patients with multiple endocrine neoplasia type 1
    Dina M Elaraj
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Surgery 134:858-64; discussion 864-5. 2003
    ..This study analyzes outcomes of a cohort of MEN1 patients undergoing initial PTx at one institution...
  70. pmc Function of non-visual arrestins in signaling and endocytosis of the gastrin-releasing peptide receptor (GRP receptor)
    Michael Schumann
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892 1804, USA
    Biochem Pharmacol 75:1170-85. 2008
    ..Our results show that both non-visual arrestins play an important role in GRP-R internalization and desensitization...
  71. ncbi request reprint Cutaneous tumors in patients with multiple endocrine neoplasm type 1 (MEN1) and gastrinomas: prospective study of frequency and development of criteria with high sensitivity and specificity for MEN1
    Behnam Asgharian
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 10, Room 9C 103, 10 Center Drive, MSC 1804, Bethesda, Maryland 20892 1804, USA
    J Clin Endocrinol Metab 89:5328-36. 2004
    ..This criterion should have sufficient sensitivity/specificity to be clinically useful...
  72. ncbi request reprint Neurotensin causes tyrosine phosphorylation of focal adhesion kinase in lung cancer cells
    Julius Leyton
    Cell and Cancer Biology Department, Medicine Branch, National Cancer Institute, National Institutes of Health, Bldg KWC, Rm 300, 9610 Medical Center Drive, Rockville, MD 20850, USA
    Eur J Pharmacol 442:179-86. 2002
    ..It remains to be determined if neurotensin receptors and focal adhesion kinase plays a role in lung cancer cellular adhesion and migration...
  73. pmc Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases
    Marc J Berna
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892 1804, USA
    Curr Top Med Chem 7:1211-31. 2007
    ..Current data from human studies of CCK2R antagonists are presented and their potential role in the treatment of these conditions reviewed. Furthermore, the role of CCK2 receptors as targets for medical imaging is discussed...
  74. ncbi request reprint Loss of heterozygosity of chromosome 1q in gastrinomas: occurrence and prognostic significance
    Yuan Jia Chen
    Digestive Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland 20892 1804, USA
    Cancer Res 63:817-23. 2003
    ..The high frequent allelic loss at 1q31-32 as well as 1q21-23, which was associated with tumor aggressive growth, suggests these two regions harbor putative tumor suppressor gene(s) that are important for aggressive growth of this tumor...
  75. ncbi request reprint Elucidation of vasoactive intestinal peptide pharmacophore for VPAC(1) receptors in human, rat, and guinea pig
    Hisato Igarashi
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Pharmacol Exp Ther 301:37-50. 2002
    ..Last, with our results a simplified, metabolically stable VIP analog was identified that should be useful as a prototype for design of selective agonists/antagonists that could be useful therapeutically...
  76. pmc Bombesin receptor-mediated imaging and cytotoxicity: review and current status
    Veronica Sancho
    Digestive Diseases Branch, National Institutes of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Curr Drug Deliv 8:79-134. 2011
    ..Both Bn receptor-mediated imaging studies as well as Bn receptor-mediated tumoral cytotoxic studies using radioactive and non-radioactive Bn-based ligands are covered...
  77. pmc Comparative analysis of diagnostic techniques for localization of gastrointestinal neuroendocrine tumors
    F Gibril
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Yale J Biol Med 70:509-22. 1997
    ..In other PETs there still is not sufficient data to establish the relative roles of EUS and SRS...
  78. pmc Bombesin marine toxin conjugates inhibit the growth of lung cancer cells
    Terry W Moody
    Department of Health and Human Services, NCI Office of the Director, CCR, Bethesda, MD 20892 USA
    Life Sci 82:855-61. 2008
    ..These results show that Hem-BB conjugates are cytotoxic for cancer cells containing BB2R...
  79. pmc Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies
    Robert T Jensen
    Digestive Diseases Branch, National Institutes of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Cancer 113:1807-43. 2008
    ..In this article, these areas are reviewed briefly along with the current state of knowledge of the PETs in these disorders, and the controversies that exist in their management are summarized briefly and discussed...
  80. ncbi request reprint Neuropeptides as autocrine growth factors in cancer cells
    Terry W Moody
    Office of the Director, CCR, National Cancer Institute, Bethesda, MD 20892, USA
    Curr Pharm Des 9:495-509. 2003
    ..VIPhybrid and SR48692, a NT receptor antagonist, potentiate the cytotoxicity of chemotherapeutic drugs. These results suggest that neuropeptide receptor antagonists may be useful in the treatment of cancer...
  81. ncbi request reprint Breast cancer VPAC1 receptors
    Terry W Moody
    Department of Health and Human Services, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Ann N Y Acad Sci 1070:436-9. 2006
    ..VIP chemotherapeutic conjugates may be useful agents to inhibit the growth of breast cancer...
  82. ncbi request reprint (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist
    Terry W Moody
    National Cancer Institute, Medicine Branch, Rockville, MD 20850, USA
    J Mol Neurosci 18:29-35. 2002
    ..Also, the increase in cAMP caused by VIP using CHO cells transfected with VPAC1 or VPAC2 receptors was antagonized by (SN)VIPhyb. These results indicate that (SN)VIPhyb is an antagonist for VPAC1, VPAC2, and PAC1 receptors...
  83. ncbi request reprint VIP as a trophic factor in the CNS and cancer cells
    Terry W Moody
    NCI Office of the Director, Center for Cancer Research, National Cancer Institute, Bldg 31, Rm 3A34, 31 Center Dr, Bethesda, MD, USA
    Peptides 24:163-77. 2003
    ..It remains to be determined if radiolabeled VIP analogs will be useful agents for early detection of cancer in patients...
  84. ncbi request reprint Nonpeptide neuromedin B receptor antagonists inhibit the proliferation of C6 cells
    T W Moody
    Cell and Cancer Biology Department, Medicine Branch, National Cancer Institute, Bldg KWC, Rm 300, 9610 Medical Center Drive, Rockville, MD 20850, USA
    Eur J Pharmacol 409:133-42. 2000
    ..PD168368 significantly inhibited C6 xenograft growth in nude mice in vivo. These results indicate that PD168368 is a C6 cell neuromedin B receptor antagonist, which inhibits proliferation...
  85. ncbi request reprint Prospective study of the ability of histamine, serotonin or serum chromogranin A levels to identify gastric carcinoids in patients with gastrinomas
    S Bashir
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892 1804, USA
    Aliment Pharmacol Ther 16:1367-82. 2002
    ..Chronic hypergastrinaemia causes gastric enterochromaffin cell proliferation and carcinoid tumours. The only reliable means to diagnose enterochromaffin cell changes/carcinoids is by biopsy...
  86. ncbi request reprint Analysis of factors associated with long-term (five or more years) cure in patients undergoing operation for Zollinger-Ellison syndrome
    H R Alexander
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Surgery 124:1160-6. 1998
    ..The purpose of this analysis was to identify perioperative factors associated with long-term (> or = 5 years) biochemical cures...
  87. ncbi request reprint CI-988 inhibits growth of small cell lung cancer cells
    T W Moody
    Department of Cell and Cancer Biology, Medicine Branch, National Cancer Institute, Rockville, Maryland 20850, USA
    J Pharmacol Exp Ther 299:1154-60. 2001
    ..Using nude mice, CI-988 inhibited the proliferation of NCI-H209 xenografts. These results suggest that CI-988 is a CCK(2) receptor antagonist that inhibits the proliferation of SCLC cells...
  88. pmc Gastric acid hypersecretory states: recent insights and advances
    Nauramy Osefo
    Digestive Diseases Branch, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 10, Room 9C 103, Bethesda, MD 20892, USA
    Curr Gastroenterol Rep 11:433-41. 2009
    ..Two new hypersecretory disorders are reviewed: rebound acid hypersecretion after the use of proton pump inhibitors and acid hypersecretion with cysteamine treatment in children with cystinosis...
  89. ncbi request reprint Tyrosine 220 in the 5th transmembrane domain of the neuromedin B receptor is critical for the high selectivity of the peptoid antagonist PD168368
    K Tokita
    Digestive Diseases Branch, NIDDK, National Institutes of Health, Bethesda, Maryland 20892-1804, USA
    J Biol Chem 276:495-504. 2001
    ..This result shows the selectivity of the peptoid PD168368, similar to that reported for numerous non-peptide analogues with other G protein-coupled receptors, is primarily dependent on interaction with transmembrane amino acids...
  90. ncbi request reprint Diagnostic uses of radiolabelled somatostatin receptor analogues in gastroenteropancreatic endocrine tumours
    F Gibril
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 10, Room 9C 103, 10 Center Drive MSC 1804, Bethesda, MD 20892 1804, USA
    Dig Liver Dis 36:S106-20. 2004
    ..Most important in this regard are the results of studies that have assessed the use of somatostatin receptor scintigraphy on clinical management. Each of these areas is reviewed in this paper...
  91. pmc Zollinger-Ellison syndrome: past, present and future controversies
    R T Jensen
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-1804, USA
    Yale J Biol Med 67:195-214. 1994
    ..An analysis of recent advances suggests there may be marked changes in the future from our current and our past approaches...
  92. pmc Activation of neuromedin B-preferring bombesin receptors on rat glioblastoma C-6 cells increases cellular Ca2+ and phosphoinositides
    L h Wang
    Digestive Diseases Branch, National Institutes of Health, Bethesda, MD 20892
    Biochem J 286:641-8. 1992
    ....
  93. ncbi request reprint Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form
    F Gibril
    Digestive Diseases Branch, National Institute of Diabetes and Digestive, and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-1804, USA
    J Clin Endocrinol Metab 86:5282-93. 2001
    ..The identification of prognostic factors that identify this group will be important clinically in allowing more aggressive treatment options to be instituted earlier...
  94. ncbi request reprint Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma
    Homayoun Shojamanesh
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892 1804, USA
    Cancer 94:331-43. 2002
    ..The purpose of the current study was to study prospectively the efficacy, safety, and effect on survival of long-term treatment with octreotide in consecutive patients with progressive malignant gastrinoma...
  95. pmc Management and outcome of patients with sporadic gastrinoma arising in the duodenum
    Theresa G Zogakis
    Surgery Branch, Center for Cancer Research, National Cancer Institute National Institutes of Health, Building 10, Room 2B07, 10 Center Drive, Bethesda, MD 20892 1502, USA
    Ann Surg 238:42-8. 2003
    ....
  96. ncbi request reprint The fifth transmembrane segment of the neuromedin B receptor is critical for high affinity neuromedin B binding
    Z Fathi
    Laboratory of Biological Chemistry, Development Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland 20892
    J Biol Chem 268:14622-6. 1993
    ..These results suggest that ILe216 in TM-V of NMB-R may be critical for high affinity NMB binding...
  97. ncbi request reprint Four amino acid residues are critical for high affinity binding of neuromedin B to the neuromedin B receptor
    E Sainz
    Laboratory of Molecular Biology, NIDCD, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Biol Chem 273:15927-32. 1998
    ..In contrast, these four amino acid substitutions in BRS-3 did not result in the formation of a high affinity binding site for the recently described non-peptide NMB-R antagonist PD168368...
  98. ncbi request reprint A new cause of Zollinger-Ellison syndrome: non-small cell lung cancer
    A Abou-Saif
    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases/NIH, Building 10, 10 Center Drive, Bethesda, Maryland 20892-1804, USA
    Gastroenterology 120:1271-8. 2001
    ..The characteristics of this case are compared with 100 cases of sporadic abdominal gastrinomas, and the evidence reviewed suggests why ZES should be considered in patients with lung cancer with peptic symptoms...
  99. ncbi request reprint Prognostic value of initial fasting serum gastrin levels in patients with Zollinger-Ellison syndrome
    A C Berger
    Surgery Branch and Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Clin Oncol 19:3051-7. 2001
    ..The level of FSG at presentation may be useful in planning the nature and extent of the initial evaluation and management in patients with sporadic ZES...
  100. ncbi request reprint Kinetics of binding of cholecystokinin to pancreatic acini
    S A Wank
    Digestive Diseases Branch, National Institute of Diabetes, and Digestive and Kidney Diseases, Bethesda, Maryland 20892
    Am J Physiol 255:G106-12. 1988
    ..Computer analysis of the inhibition of 125I-CCK-8 by CCK-8 under experimental conditions where the rapidly dissociating state predominates demonstrated a complete loss of high-affinity binding sites.(ABSTRACT TRUNCATED AT 250 WORDS)..